Supernus Pharmaceuticals
SUPN
93 hedge funds and large institutions have $309M invested in Supernus Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 36 increasing their positions, 25 reducing their positions, and 11 closing their positions.
93% more call options, than puts
Call options by funds: $2.13M | Put options by funds: $1.1M
45% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 11
44% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 25
6% more funds holding
Funds holding: 88 → 93 (+5)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
24% less capital invested
Capital invested by funds: $405M → $309M (-$95.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MRM
Michael R. Murphy
|
+$3.52M |
| 2 |
BC
Bruce & Co
Chicago,
Illinois
|
+$2.71M |
| 3 |
Millennium Management
New York
|
+$2.46M |
| 4 |
JG
Jefferies Group
New York
|
+$2.33M |
| 5 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$2.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$15.8M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$9.68M |
| 3 |
A
Abingworth
London,
United Kingdom
|
-$6.51M |
| 4 |
NCGI
Next Century Growth Investors
Plymouth,
Minnesota
|
-$5.05M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$2.37M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GC
101
Guggenheim Capital
Chicago,
Illinois
| – | -$122K | -11,187 | Closed |
|
|
FMT
102
First Mercantile Trust
Cordova,
Tennessee
| – | -$48K | -4,380 | Closed |
|
|
VFA
103
Virtus Fund Advisers
Hartford,
Connecticut
| – | -$27K | -2,498 | Closed |
|
104
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$11K | -1,010 | Closed |
|
SUPN Hedge Fund Activity: Q3 2014 in Review
93 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q3 2014, worth a combined $309M — down 24% from $405M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new SUPN positions and 11 closed out — a net gain of 5 holders — while 36 added to existing stakes and 25 trimmed.
The largest buyer was Michael R. Murphy, adding an estimated $3.52M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $15.8M sold.
- 93 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q3 2014, up from 88 in Q2 2014.
- Funds reported $309M of Supernus Pharmaceuticals stock for Q3 2014, down 24% quarter-over-quarter.
- 16 funds opened new Supernus Pharmaceuticals positions in Q3 2014 and 11 closed out, a net change of +5 holders.
- The largest Supernus Pharmaceuticals buyer in Q3 2014 was Michael R. Murphy, an estimated $3.52M added.
- The largest Supernus Pharmaceuticals seller in Q3 2014 was Consonance Capital Management, an estimated $15.8M sold.
Based on aggregated 13F filings for Q3 2014.